These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 19903294)

  • 1. CD133+ cell content does not influence recovery time after hematopoietic stem cell transplantation.
    Jaime-Pérez JC; Guillermo-Villanueva VA; Méndez-Ramírez N; Chapa-Rodríguez A; Gutiérrez-Aguirre H; Gómez-Almaguer D
    Transfusion; 2009 Nov; 49(11):2390-4. PubMed ID: 19903294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mobilization kinetics of CD133+ hematoprogenitor cells for hematopoietic grafting.
    Jaime-Pérez JC; Hernández-Alcántara AE; Méndez-Ramírez N; Vázquez-Garza E; Cantú-Rodríguez OG; Gómez-Almaguer D
    Transfusion; 2009 Mar; 49(3):532-5. PubMed ID: 19243545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positive selection and transplantation of autologous highly purified CD133(+) stem cells in resistant/relapsed chronic lymphocytic leukemia patients results in rapid hematopoietic reconstitution without an adequate leukemic cell purging.
    Isidori A; Motta MR; Tani M; Terragna C; Zinzani P; Curti A; Rizzi S; Taioli S; Giudice V; D'Addio A; Gugliotta G; Conte R; Baccarani M; Lemoli RM
    Biol Blood Marrow Transplant; 2007 Oct; 13(10):1224-32. PubMed ID: 17889360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD133+CD34+ and CD133+CD38+ blood progenitor cells as predictors of platelet engraftment in patients undergoing autologous peripheral blood stem cell transplantation.
    Camacho Villa AY; Reyes Maldonado E; Montiel Cervantes LA; Vela Ojeda J
    Transfus Apher Sci; 2012 Jun; 46(3):239-44. PubMed ID: 22386660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
    Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
    Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transplantation of purified autologous leukapheresis-derived CD34+ and CD133+ stem cells for patients with chronic spinal cord injuries: long-term evaluation of safety and efficacy.
    Al-Zoubi A; Jafar E; Jamous M; Al-Twal F; Al-Bakheet S; Zalloum M; Khalifeh F; Radi SA; El-Khateeb M; Al-Zoubi Z
    Cell Transplant; 2014; 23 Suppl 1():S25-34. PubMed ID: 25372344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD133 allows elaborated discrimination and quantification of haematopoietic progenitor subsets in human haematopoietic stem cell transplants.
    Radtke S; Görgens A; Kordelas L; Schmidt M; Kimmig KR; Köninger A; Horn PA; Giebel B
    Br J Haematol; 2015 Jun; 169(6):868-78. PubMed ID: 25819405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation.
    Kiss JE; Rybka WB; Winkelstein A; deMagalhaes-Silverman M; Lister J; D'Andrea P; Ball ED
    Bone Marrow Transplant; 1997 Feb; 19(4):303-10. PubMed ID: 9051238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viable CD34+/CD133+ blood progenitor cell dose as a predictor of haematopoietic engraftment in multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation.
    Hicks C; Wong R; Manoharan A; Kwan YL
    Ann Hematol; 2007 Aug; 86(8):591-8. PubMed ID: 17492259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation.
    Bence-Bruckler I; Bredeson C; Atkins H; McDiarmid S; Hamelin L; Hopkins H; Perry G; Genest P; Huebsch L
    Bone Marrow Transplant; 1998 Nov; 22(10):965-9. PubMed ID: 9849693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors that influence the collection and engraftment of allogeneic peripheral-blood stem cells in patients with hematologic malignancies.
    Brown RA; Adkins D; Goodnough LT; Haug JS; Todd G; Wehde M; Hendricks D; Ehlenbeck C; Laub L; DiPersio J
    J Clin Oncol; 1997 Sep; 15(9):3067-74. PubMed ID: 9294469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience.
    Olivieri A; Offidani M; Montanari M; Ciniero L; Cantori I; Ombrosi L; Masia CM; Centurioni R; Mancini S; Brunori M; Leoni P
    Haematologica; 1998 Apr; 83(4):329-37. PubMed ID: 9592983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous transplantation of blood stem cells mobilized with filgrastim alone in 93 patients with malignancies: the number of CD34+ cells reinfused is the only factor predicting both granulocyte and platelet recovery.
    Faucher C; Le Corroller AG; Chabannon C; Viens P; Stoppa AM; Bouabdallah R; Camerlo J; Vey N; Gravis G; Gastaut JA; Novakovitch G; Mannoni P; Bardou VJ; Moatti JP; Maraninchi D; Blaise D
    J Hematother; 1996 Dec; 5(6):663-70. PubMed ID: 9117255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term hematopoietic engraftment after autologous peripheral blood progenitor cell transplantation in pediatric patients: effect of the CD34+ cell dose.
    Diaz MA; Vicent MG; Garcia-Sanchez F; Vicario JL; Madero L
    Vox Sang; 2000; 79(3):145-50. PubMed ID: 11111232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of poor marrow graft function with allogeneic CD34+ cells immunoselected from G-CSF-mobilized peripheral blood progenitor cells of the marrow donor.
    Arseniev L; Tischler HJ; Battmer K; Südmeier I; Casper J; Link H
    Bone Marrow Transplant; 1994 Nov; 14(5):791-7. PubMed ID: 7534162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased number of circulating progenitor cells after implantation of ventricular assist devices.
    Manginas A; Tsiavou A; Sfyrakis P; Giamouzis G; Tsourelis L; Leontiadis E; Degiannis D; Cokkinos DV; Alivizatos PA
    J Heart Lung Transplant; 2009 Jul; 28(7):710-7. PubMed ID: 19560700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [CD34+ cell dose and hematologic recovery in allogeneic peripheral blood stem cell transplantation].
    Sawada H; Wake A; Yamasaki Y; Izumi Y
    Rinsho Ketsueki; 2000 Jun; 41(6):500-6. PubMed ID: 10921350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Innovative two-step negative selection of granulocyte colony-stimulating factor-mobilized circulating progenitor cells: adequacy for autologous and allogeneic transplantation.
    Rambaldi A; Borleri G; Dotti G; Bellavita P; Amaru R; Biondi A; Barbui T
    Blood; 1998 Mar; 91(6):2189-96. PubMed ID: 9490708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD34+ cell enrichment for autologous peripheral blood stem cell transplantation by use of the CliniMACs device.
    Després D; Flohr T; Uppenkamp M; Baldus M; Hoffmann M; Huber C; Derigs HG
    J Hematother Stem Cell Res; 2000 Aug; 9(4):557-64. PubMed ID: 10982256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation of purified autologous peripheral blood CD34+ cells with low T cell content using CliniMACS device--a local experience.
    Leong CF; Habsah A; Teh HS; Goh KY; Fadilah SA; Cheong SK
    Malays J Pathol; 2008 Jun; 30(1):31-6. PubMed ID: 19108409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.